Table 2.
HPV vaccines as of September 2022.
| Manufacturer, Product | Subtype | Indicated for | Status |
|---|---|---|---|
| GlaxoSmithKline (GSK), Rixensart, Belgium Cervarix® |
Bivalent | Persons 9–45 years of age | Licensed and prequalified |
| Xiamen Innovax Biotech subsidiary of Beijing Wantai, Xiamen, Fujian, China Cecolin® |
Bivalent | Females 9–45 years of age | Licensed and prequalified |
| Shanghai Zerun, subsidiary of Yunnan Walvax Biotechnology, Shanghai, China Walrinvax®/Wo Ze Hui® |
Bivalent | Females 9–30 years of age | Licensed in China |
| Merck Sharpe & Dohme (MSD), Rahway, NJ, USA Gardasil® |
Quadrivalent | Persons 9–45 years of age | Licensed and prequalified |
| Serum Institute of India, Pune, India CERVAVAC qHPV® |
Quadrivalent | Persons 9–26 years of age | Licensed in India |
| Merck Sharpe & Dohme, Rahway, NJ, USA Gardasil 9® |
Nonavalent | Persons 9–45 years of age | Licensed and prequalified |
| China National Biotec Group, Beijing, China | Quadrivalent | To be confirmed | Phase 3 clinical trial |
| Nanolek, Moscow, Russian Federation | Quadrivalent | To be confirmed | Phase 3 clinical trial |
| Beijing Health Guard, Beijing, China | Quadrivalent | females 20–45 | Phase 3 clinical trial |
| Bowei Biologics, Tianjin, China | Quadrivalent | females 9–45 | Phase 3 clinical trial |
| Shanghai Zerun, subsidiary of Yunnan Walvax Biotechnology, Shanghai, China | Nonavalent | females 9–45 | Phase 3 clinical trial |
| Xiamen Innovax Biotech subsidiary of Beijing Wantai, Xiamen, Fujian, China NCT04537156 |
Nonavalent | females 18–45 | Phase 3 clinical trial |
| Jangsu Recbio Technology, Taizhou, Jiangsu, China REC603 |
Nonavalent | females 9–45 | Phase 3 clinical trial |
Bivalent: includes HPV subtypes 16 and 18. Quadrivalent: includes subtypes 6, 11, 16, and 18. Nonavalent: includes subtypes 6, 11, 16, 18, 31, 33, 45, 52, and 58.